OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 23:46 UTC. Every row links to its source record.

MYBL1 MYB proto-oncogene like 1

ENSG00000185697 · protein coding · Open Targets profile

Transcription factor that specifically recognizes the sequence 5'-YAAC[GT]G-3' (PubMed:7987850, PubMed:8058310). Acts as a master regulator of male meiosis by promoting expression of piRNAs: activates expression of both piRNA precursor RNAs and expression of protein-coding genes involved in piRNA metabolism (By similarity). The piRNA metabolic process mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons, which is essential for the germline integrity (By similarity). Transcriptional activator of SOX30 (By similarity). {ECO:0000250|UniProtKB:P51960, ECO:0000269|PubMed:7987850, ECO:0000269|PubMed:8058310}.

MYBL1: inherited and tumour-mutation evidence across 15 cancers

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751hepatocellular carcinomahepatocellular carcinomatriple-negative breast carcinomatriple-negative breast carcinomagliomagliomacentral nervous system cancercentral nervous system canceradrenal cortex carcinomaadrenal cortex carcinomanonpapillary renal cell carcinomanonpapillary renal cell carcinomatesticular germ cell tumortesticular germ cell tumordiffuse astrocytomadiffuse astrocytomaaneurysmal bone cystaneurysmal bone cystadrenocortical carcinoma, hereditaryadrenocortical carcinoma, hereditaryadenoid cystic carcinomaadenoid cystic carcinomaastrocytoma (excluding glioblastoma)astrocytoma (excluding glioblastoma)Mayer-Rokitansky-Küster-Hauser syndrome…Mayer-Rokitansky-Küster-Hauser syndrome type 2Mayer-Rokitansky-Kuster-Hauser syndromeMayer-Rokitansky-Kuster-Hauser syndromepancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.17649999260902405 (upper bound 0.26475000381469727). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of MYBL1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of MYBL1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.